Mercaptopurine Accord (Mercaptopurine Monohydrate)

After oral administration, mercaptopurine is metabolised to active thioguanine nucleotides that block de novo purine synthesis and become incorporated into DNA and RNA. This disrupts nucleic‑acid function, leading to cytotoxicity in rapidly dividing cells and suppresses immune cell proliferation, which is useful in both cancer and autoimmune conditions.

The dose of Mercaptopurine Accord is individualized by the prescribing clinician based on factors such as the patient’s body surface area, disease type, treatment phase, and results of thiopurine methyltransferase (TPMT) testing. No fixed dosing regimen is provided here; the prescriber will set the appropriate amount.

Mercaptopurine is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should only be used during pregnancy if the potential benefit justifies the risk. Breastfeeding is also not recommended because the drug is excreted in milk and may affect the infant. Consultation with a specialist is essential.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Mercaptopurine Accord. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both mercaptopurine and azathioprine are thiopurine antimetabolites that interfere with purine synthesis. Mercaptopurine is the active metabolite of azathioprine, offering a more direct pharmacologic effect. Dosing and toxicity profiles are similar, but mercaptopurine may be preferred when precise dose titration is required, while azathioprine is often used for its convenient oral formulation.

Store Mercaptopurine Accord at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture, direct sunlight and excessive heat. Do not store in the bathroom or near a kitchen sink where humidity is high.

Mercaptopurine Accord is taken orally as a tablet with a glass of water. It may be taken with or without food, but consistent administration with respect to meals helps maintain stable blood levels. Patients should follow the prescriber’s instructions regarding timing and any required dose adjustments.

The most serious risks include bone‑marrow suppression leading to severe anemia or neutropenia, hepatotoxicity with elevated liver enzymes or liver injury, life‑threatening infections due to immunosuppression, pancreatitis, and rare secondary malignancies. Prompt reporting of fever, unusual bruising, jaundice or persistent abdominal pain to a healthcare professional is essential.

Mercaptopurine should be avoided in patients with known hypersensitivity to the drug, severe hepatic impairment, active uncontrolled infections, or documented TPMT deficiency that cannot be safely managed. Pregnant women and breastfeeding mothers should also refrain from use unless the benefits outweigh the risks and under close medical supervision.